title: High expression of Dicer reveals a negative prognostic influence in certain subtypes of primary cutaneous T cell lymphomas.
abstract: BACKGROUND
  Aberrant expression of microRNAs (miRNAs) has been implicated in oncogenesis of various tumors and primary cutaneous T cell lymphomas. Dicer, a ribonuclease III-like enzyme is essential for miRNA processing.
  
  
  OBJECTIVE
  We initiated a retrospective study to characterize the alterations in the expression profile of Dicer in patients with primary cutaneous T cell lymphomas (CTCL).
  
  
  METHODS
  A total of 50 consecutive patients with primary CTCL were studied, with the majority having mycosis fungoides (n=34). Five patients had primary cutaneous CD 30+ anaplastic large cell lymphoma, four patients each had lymphomatoid papulosis and primary cutaneous CD4-positive small/medium T-cell lymphoma, one primary cutaneous γδ T cell lymphoma, one Sézary syndrome and another subcutaneous panniculitis-like T cell lymphoma of αβ-phenotype. Immunohistochemistry was performed on paraffin sections using a commercially available antibody against Dicer. Intensity of expression was correlated with clinical parameters including disease specific survival (DSS) and time to progression (TTP).
  
  
  RESULTS
  After a median follow-up of 74 months (range: 1-271), 12/50 patients (24%) have died. Univariate and multivariate analysis for disease-specific survival showed Dicer expression and stage as a negative predictive factor in the sole group of MF patients (n=34) as well as in the heterogeneous group of patients (n=50), but not gender, histological subtype, primary localization of disease, age and recurrence of lymphoma (p>0.05).
  
  
  CONCLUSIONS
  Our data suggest Dicer expression as a possible molecular marker in patients with MF and apparently indicate that miRNA(s) might be of clinical relevance in CTCL.
authors.affiliation: Department of Dermatology, Medical University of Vienna, Austria. julia.valencak@meduniwien.ac.at
authors.forename: Julia
authors.initials: J
authors.lastname: Valencak
authors.forename: Katharina
authors.initials: K
authors.lastname: Schmid
authors.forename: Franz
authors.initials: F
authors.lastname: Trautinger
authors.forename: Werner
authors.initials: W
authors.lastname: Wallnöfer
authors.forename: Leonhard
authors.initials: L
authors.lastname: Muellauer
authors.forename: Afschin
authors.initials: A
authors.lastname: Soleiman
authors.forename: Robert
authors.initials: R
authors.lastname: Knobler
authors.forename: Andrea
authors.initials: A
authors.lastname: Haitel
authors.forename: Hubert
authors.initials: H
authors.lastname: Pehamberger
authors.forename: Markus
authors.initials: M
authors.lastname: Raderer
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001317:Austria; D014408:Biomarkers, Tumor / Q000032:analysis*; D053487:DEAD-box RNA Helicases / Q000032:analysis*; D018450:Disease Progression; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D053208:Kaplan-Meier Estimate; D054446:Lymphoma, Primary Cutaneous Anaplastic Large Cell / Q000201:enzymology; D016399:Lymphoma, T-Cell / Q000201:enzymology; D016410:Lymphoma, T-Cell, Cutaneous / Q000201:enzymology* / Q000235:genetics / Q000401:mortality / Q000473:pathology / Q000628:therapy; D017731:Lymphomatoid Papulosis / Q000201:enzymology; D008297:Male; D008875:Middle Aged; D009182:Mycosis Fungoides / Q000201:enzymology; D009367:Neoplasm Staging; D015434:Panniculitis / Q000201:enzymology; D016016:Proportional Hazards Models; D012189:Retrospective Studies; D043244:Ribonuclease III / Q000032:analysis*; D018570:Risk Assessment; D012307:Risk Factors; D012751:Sezary Syndrome / Q000201:enzymology; D012878:Skin Neoplasms / Q000201:enzymology* / Q000235:genetics / Q000401:mortality / Q000473:pathology / Q000628:therapy; D015996:Survival Rate; D013997:Time Factors; D016896:Treatment Outcome; D015854:Up-Regulation
chemical_list: D014408:Biomarkers, Tumor; C408087:DICER1 protein, human; D043244:Ribonuclease III; D053487:DEAD-box RNA Helicases